Cargando…

Sensitivity to Anticancer Agents and Resistance Mechanisms in Clear Cell Carcinoma of the Ovary

We conducted the present study to determine the chemoresistance mechanisms in clear cell carcinoma of the ovary (CCC). Five human CCC cell lines (HAC‐2, RMG‐I, RMG‐II, KK, and KOC‐7c) were used in this study. The sensitivity of the cells to the anticancer agents was determined by 3–(4,5–dimethylthia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Itamochi, Hiroaki, Kigawa, Junzo, Sultana, Habiba, Iba, Takahiro, Akeshima, Ryoji, Kamazawa, Shunji, Kanamori, Yasunobu, Terakawa, Naoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2002
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927055/ https://www.ncbi.nlm.nih.gov/pubmed/12079522 http://dx.doi.org/10.1111/j.1349-7006.2002.tb01312.x

Ejemplares similares

Telomerase activity and p53-dependent apoptosis in ovarian cancer cells
por: Akeshima, R, et al.
Publicado: (2001)

Enhanced Topoisomerase I Activity and Increased Topoisomerase IIα Content in Cisplatin‐resistant Cancer Cell Lines
por: Minagawa, Yukihisa, et al.
Publicado: (1997)

Cisplatin‐resistant HeLa Cells Are Resistant to Apoptosis via p53‐dependent and ‐independent Pathways
por: Minagawa, Yukihisa, et al.
Publicado: (1999)

Synergistic Enhancement of Cisplatin Cytotoxicity by SN‐38, an Active Metabolite of CPT‐11, for Cisplatin‐resistant HeLa Cells
por: Minagawa, Yukihisa, et al.
Publicado: (1994)

Nedaplatin: a cisplatin derivative in cancer chemotherapy
por: Shimada, Muneaki, et al.
Publicado: (2013)

Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma
por: Miyata, Kohei, et al.
Publicado: (2014)

Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma
por: Itamochi, Hiroaki, et al.
Publicado: (2017)

Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary
por: Takahashi, Ryoko, et al.
Publicado: (2016)

Surgical management of non-invasive uterine clear cell carcinoma
por: Sugiyama, Toru, et al.
Publicado: (2017)

An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
por: Shoji, Tadahiro, et al.
Publicado: (2018)

Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents
por: Takatori, Eriko, et al.
Publicado: (2012)

Somatic Copy Number Alterations Associated with Japanese or Endometriosis in Ovarian Clear Cell Adenocarcinoma
por: Okamoto, Aikou, et al.
Publicado: (2015)

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging
por: Takano, M, et al.
Publicado: (2006)

Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target
por: Tsang, Tsun Yee, et al.
Publicado: (2017)

Clinicopathological correlations of endometrioid and clear cell carcinomas in the uterus and ovary
por: Mori, Hidemi, et al.
Publicado: (2023)

Borderline Clear Cell Adenofibroma of the Ovary
por: Kleebkaow, Pilaiwan, et al.
Publicado: (2017)

Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Clear-Cell Carcinoma of the Ovary with Bilateral Breast Metastases
por: Galili, Yehuda, et al.
Publicado: (2019)

Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries
por: Zhang, Xiaonan, et al.
Publicado: (2021)

Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review)
por: UEKURI, CHIHARU, et al.
Publicado: (2013)

Ruptured clear cell carcinoma of the ovary presenting as acute abdomen
por: Zhou, Zhen Ni, et al.
Publicado: (2016)

Clear Cell Borderline Tumor of the Ovary: A Case Report
Publicado: (2023)

A Case of Torsion in an Otherwise-Normal Ovary with a Giant Hematosalpinx Larger than Enlarged Ovary: Utilization of Diagnostic Laparoscopy for the Accurate Diagnosis
por: Yu, Sae, et al.
Publicado: (2021)

Flavonoids as Anticancer Agents
por: Kopustinskiene, Dalia M., et al.
Publicado: (2020)

Profile of farletuzumab and its potential in the treatment of solid tumors
por: Sato, Seiya, et al.
Publicado: (2016)

Anticancer agents : frontiers in cancer chemotherapy /
Publicado: (2001)

Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents
por: Nonomura, Yuki, et al.
Publicado: (2022)

Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C
por: Kolendowski, Bart, et al.
Publicado: (2020)

Clear cell carcinoma of the ovary: Is there a role of histology-specific treatment?
por: Takano, Masashi, et al.
Publicado: (2012)

Clear cell carcinoma of the ovary: multi-slice computed tomography findings
por: Li, Xubin, et al.
Publicado: (2015)

Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives
por: Mabuchi, Seiji, et al.
Publicado: (2016)

Agent-based modeling and simulation with Swarm
por: Iba, Hitoshi
Publicado: (2013)

Radiation Recall with Anticancer Agents
por: Burris, Howard A., et al.
Publicado: (2010)

Bacteriocins as Potential Anticancer Agents
por: Kaur, Sumanpreet, et al.
Publicado: (2015)

Anticancer Agents Targeted to Sirtuins
por: Kozako, Tomohiro, et al.
Publicado: (2014)

Thiadiazole derivatives as anticancer agents
por: Szeliga, Monika
Publicado: (2020)

Benzothiazole derivatives as anticancer agents
por: Irfan, Ali, et al.
Publicado: (2019)

Polyoxometalates Impact as Anticancer Agents
por: Carvalho, Fátima, et al.
Publicado: (2023)

Menthol: An underestimated anticancer agent
por: Zhao, Yijia, et al.
Publicado: (2023)

Clearing and Masking Agents in Pretargeting Strategies
por: Staudt, Markus, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qm5ae669h9nsmdjh3e8lognjs1